

Brendan Saloner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1922879/publications.pdf>

Version: 2024-02-01

130
papers

4,000
citations

147566

31
h-index

143772

57
g-index

131
all docs

131
docs citations

131
times ranked

3731
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010. JAMA Internal Medicine, 2014, 174, 1668.	2.6	553
2	An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. Annals of Internal Medicine, 2020, 173, 57-58.	2.0	278
3	Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. JAMA - Journal of the American Medical Association, 2015, 314, 1515.	3.8	191
4	A Public Health Strategy for the Opioid Crisis. Public Health Reports, 2018, 133, 24S-34S.	1.3	156
5	Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. Health Affairs, 2017, 36, 2046-2053.	2.5	120
6	Primary Care Access for New Patients on the Eve of Health Care Reform. JAMA Internal Medicine, 2014, 174, 861.	2.6	117
7	Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction, 2020, 115, 1683-1694.	1.7	95
8	The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample. Drug and Alcohol Dependence, 2017, 175, 157-163.	1.6	91
9	The emerging public discourse on state legalization of marijuana for recreational use in the US: Analysis of news media coverage, 2010-2014. Preventive Medicine, 2016, 90, 114-120.	1.6	88
10	Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality. Annals of Internal Medicine, 2019, 171, 1.	2.0	86
11	Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework. Milbank Quarterly, 2020, 98, 700-746.	2.1	86
12	Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion. JAMA Network Open, 2018, 1, e181588.	2.8	82
13	Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug and Alcohol Dependence, 2017, 178, 512-518.	1.6	79
14	Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population. Medical Care, 2017, 55, 669-676.	1.1	73
15	An ACA Provision Increased Treatment For Young Adults With Possible Mental Illnesses Relative To Comparison Group. Health Affairs, 2014, 33, 1425-1434.	2.5	70
16	Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder. Journal of Adolescent Health, 2017, 60, 747-750.	1.2	67
17	Insurance Coverage and Treatment Use Under the Affordable Care Act Among Adults With Mental and Substance Use Disorders. Psychiatric Services, 2017, 68, 542-548.	1.1	59
18	Changes in Primary Care Access Between 2012 and 2016 for New Patients With Medicaid and Private Coverage. JAMA Internal Medicine, 2017, 177, 588.	2.6	56

#	ARTICLE	IF	CITATIONS
19	Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. <i>Journal of Substance Abuse Treatment</i> , 2021, 126, 108329.	1.5	56
20	Justice-Involved Adults With Substance Use Disorders: Coverage Increased But Rates Of Treatment Did Not In 2014. <i>Health Affairs</i> , 2016, 35, 1058-1066.	2.5	54
21	COVID-19 Incidence and Mortality in Federal and State Prisons Compared With the US Population, April 5, 2020, to April 3, 2021. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1865.	3.8	51
22	Predictors of Overdose Death Among High-Risk Emergency Department Patients With Substance-Related Encounters: A Data Linkage Cohort Study. <i>Annals of Emergency Medicine</i> , 2020, 75, 1-12.	0.3	48
23	Specialty Substance Use Disorder Treatment Admissions Steadily Increased In The Four Years After Medicaid Expansion. <i>Health Affairs</i> , 2020, 39, 453-461.	2.5	44
24	Access to Health Insurance and Utilization of Substance Use Disorder Treatment: Evidence from the Affordable Care Act Dependent Coverage Provision. <i>Health Economics (United Kingdom)</i> , 2018, 27, 50-75.	0.8	41
25	Therapies Offered at Residential Addiction Treatment Programs in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 804.	3.8	41
26	Moving Addiction Care to the Mainstream – Improving the Quality of Buprenorphine Treatment. <i>New England Journal of Medicine</i> , 2018, 379, 4-6.	13.9	40
27	Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder. <i>Journal of Adolescent Health</i> , 2020, 67, 542-549.	1.2	38
28	Article Commentary: It Will End in Tiers: A Strategy to Include “Dabblers” in the Buprenorphine Workforce after the X-Waiver. <i>Substance Abuse</i> , 2021, 42, 153-157.	1.1	37
29	Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. <i>JAMA Internal Medicine</i> , 2021, 181, 562.	2.6	37
30	Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2206.	3.8	35
31	Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder. <i>JAMA Pediatrics</i> , 2017, 171, 729.	3.3	33
32	Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015. <i>Psychiatric Services</i> , 2018, 69, 832-835.	1.1	33
33	Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. <i>Psychiatric Services</i> , 2016, 67, 676-679.	1.1	32
34	Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey. <i>International Journal of Drug Policy</i> , 2022, 101, 103537.	1.6	31
35	Predicting Opioid Overdose Deaths Using Prescription Drug Monitoring Program Data. <i>American Journal of Preventive Medicine</i> , 2019, 57, e211-e217.	1.6	29
36	Predictive Modeling of Opioid Overdose Using Linked Statewide Medical and Criminal Justice Data. <i>JAMA Psychiatry</i> , 2020, 77, 1155.	6.0	28

#	ARTICLE	IF	CITATIONS
37	Access Points for the Underserved. <i>Medical Care</i> , 2014, 52, 818-825.	1.1	27
38	Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons. <i>Journal of Addiction Medicine</i> , 2020, 14, e257-e260.	1.4	25
39	Opioid overdose death following criminal justice involvement: Linking statewide corrections and hospital databases to detect individuals at highest risk. <i>Drug and Alcohol Dependence</i> , 2020, 213, 107997.	1.6	25
40	Access and enrollment in safety net programs in the wake of COVID-19: A national cross-sectional survey. <i>PLoS ONE</i> , 2020, 15, e0240080.	1.1	25
41	The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act. <i>Journal of Policy Analysis and Management</i> , 2019, 38, 366-93.	1.1	25
42	Substance Use Treatment Provider Behavior and Healthcare Reform: Evidence from Massachusetts. <i>Health Economics (United Kingdom)</i> , 2018, 27, 76-101.	0.8	24
43	Association Between Medicaid Expansion and Rates of Opioid-Related Hospital Use. <i>JAMA Internal Medicine</i> , 2020, 180, 753.	2.6	24
44	Pinching the Poor? Medicaid Cost Sharing under the ACA. <i>New England Journal of Medicine</i> , 2014, 370, 1177-1180.	13.9	23
45	Physician Time Burden Associated with Querying Prescription Drug Monitoring Programs. <i>Pain Medicine</i> , 2018, 19, 1952-1960.	0.9	23
46	Community Health Centers and Access to Care Among Underserved Populations: A Synthesis Review. <i>Medical Care Research and Review</i> , 2020, 77, 3-18.	1.0	23
47	US Adults' Preferences for Public Allocation of a Vaccine for Coronavirus Disease 2019. <i>JAMA Network Open</i> , 2020, 3, e2023020.	2.8	23
48	Spanish-speaking Immigrants' Access to Safety Net Providers and Translation Services Across Traditional and Emerging US Destinations. <i>Milbank Quarterly</i> , 2016, 94, 768-799.	2.1	22
49	Non-buprenorphine opioid utilization among patients using buprenorphine. <i>Addiction</i> , 2017, 112, 1045-1053.	1.7	22
50	Declining Medicaid Fees and Primary Care Appointment Availability for New Medicaid Patients. <i>JAMA Internal Medicine</i> , 2018, 178, 145.	2.6	22
51	Admission Practices And Cost Of Care For Opioid Use Disorder At Residential Addiction Treatment Programs In The US. <i>Health Affairs</i> , 2021, 40, 317-325.	2.5	20
52	The Role of Screening in Depression Diagnosis and Treatment in a Representative Sample of US Primary Care Visits. <i>Journal of General Internal Medicine</i> , 2020, 35, 12-20.	1.3	19
53	COVID-19 Cases Among Employees of U.S. Federal and State Prisons. <i>American Journal of Preventive Medicine</i> , 2021, 60, 840-844.	1.6	19
54	Most Uninsured Adults Could Schedule Primary Care Appointments Before The ACA, But Average Price Was \$160. <i>Health Affairs</i> , 2015, 34, 773-780.	2.5	18

#	ARTICLE	IF	CITATIONS
55	Availability of New Medicaid Patient Appointments and the Role of Rural Health Clinics. <i>Health Services Research</i> , 2016, 51, 570-591.	1.0	17
56	Heterogeneity in prenatal substance use screening despite universal screening recommendations: findings from the Pregnancy Risk Assessment Monitoring System, 2016-2018. <i>American Journal of Obstetrics & Gynecology</i> MFM, 2021, 3, 100419.	1.3	17
57	Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2022, 3, e220093.	1.0	17
58	Changes in Outpatient Services and Medication Use Following a Non-fatal Opioid Overdose in the West Virginia Medicaid Program. <i>Journal of General Internal Medicine</i> , 2019, 34, 789-791.	1.3	16
59	A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients. <i>Drug and Alcohol Dependence</i> , 2019, 201, 127-133.	1.6	16
60	Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108512.	1.6	16
61	Covering Undocumented Immigrants "State Innovation in California. <i>New England Journal of Medicine</i> , 2016, 375, 1913-1915.	13.9	15
62	Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters. <i>Addiction</i> , 2021, 116, 3473-3481.	1.7	15
63	Can Appealing to Patient Altruism Reduce Overuse of Health Care Services? An Experimental Survey. <i>Journal of General Internal Medicine</i> , 2017, 32, 732-738.	1.3	14
64	The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia. <i>Health Affairs</i> , 2019, 38, 633-642.	2.5	14
65	Policy Strategies to Reduce Youth Recreational Marijuana Use. <i>Pediatrics</i> , 2015, 135, 955-957.	1.0	13
66	An Update on "Insurance Coverage and Treatment Use Under the Affordable Care Act Among Adults With Mental and Substance Use Disorders". <i>Psychiatric Services</i> , 2017, 68, 310-311.	1.1	13
67	Is screening and intervention associated with treatment receipt among individuals with alcohol use disorder? Evidence from a national survey. <i>Journal of Substance Abuse Treatment</i> , 2018, 92, 85-90.	1.5	12
68	Use of Opioid Overdose Deaths Reported in One State's Criminal Justice, Hospital, and Prescription Databases to Identify Risk of Opioid Fatalities. <i>JAMA Internal Medicine</i> , 2019, 179, 980.	2.6	12
69	Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. <i>JAMA Network Open</i> , 2021, 4, e2138807.	2.8	12
70	Cost Sharing in Medicaid: Assumptions, Evidence, and Future Directions. <i>Medical Care Research and Review</i> , 2016, 73, 383-409.	1.0	11
71	Price Transparency in Primary Care: Can Patients Learn About Costs When Scheduling an Appointment?. <i>Journal of General Internal Medicine</i> , 2017, 32, 815-821.	1.3	11
72	Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis. <i>Health Affairs</i> , 2020, 39, 740-746.	2.5	11

#	ARTICLE	IF	CITATIONS
73	Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109089.	1.6	11
74	Methadone on Wheels—A New Option to Expand Access to Care Through Mobile Units. <i>JAMA Psychiatry</i> , 2022, 79, 187.	6.0	11
75	Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. <i>JAMA Network Open</i> , 2021, 4, e2123019.	2.8	10
76	Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative. <i>Addiction Science & Clinical Practice</i> , 2022, 17, .	1.2	10
77	A Stronger Treatment System for Opioid Use Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2165.	3.8	9
78	Association Between the Number of Certified Buprenorphine Prescribers and the Quantity of Buprenorphine Prescriptions: Evidence from 2015 to 2017. <i>Journal of General Internal Medicine</i> , 2019, 34, 2313-2315.	1.3	9
79	Geographic location of buprenorphine-waivered physicians and integration with health systems. <i>Journal of Substance Abuse Treatment</i> , 2020, 115, 108034.	1.5	9
80	Opioid agonist treatment is highly protective against overdose death among a U.S. statewide population of justice-involved adults. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 117-126.	1.1	9
81	Clinical Risk Factors for COVID-19 Among People With Substance Use Disorders. <i>Psychiatric Services</i> , 2020, 71, 1308-1308.	1.1	9
82	Physicians as a Source of Medications for Nonmedical Use: Comparison of Opioid Analgesic, Stimulant, and Sedative Use in a National Sample. <i>Psychiatric Services</i> , 2017, 68, 56-62.	1.1	8
83	Changes in spending and service use after a state autism insurance mandate. <i>Autism</i> , 2019, 23, 167-174.	2.4	8
84	Integrated care models and behavioral health care utilization: Quasi-experimental evidence from Medicaid health homes. <i>Health Economics (United Kingdom)</i> , 2020, 29, 1086-1097.	0.8	8
85	Quality of Preventive and Chronic Illness Care for Insured Adults With Opioid Use Disorder. <i>JAMA Network Open</i> , 2021, 4, e214925.	2.8	8
86	Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. <i>Annals of Emergency Medicine</i> , 2022, 79, 441-450.	0.3	8
87	Second-Generation Antipsychotic Use Among Stimulant-Using Children, by Organization of Medicaid Mental Health. <i>Psychiatric Services</i> , 2014, 65, 1458-1464.	1.1	7
88	Tobacco Screening and Counseling in the U.S.: Smokers With Mental Health and Substance Use Problems. <i>American Journal of Preventive Medicine</i> , 2018, 55, 524-532.	1.6	7
89	The Impact of Various Risk Assessment Time Frames on the Performance of Opioid Overdose Forecasting Models. <i>Medical Care</i> , 2020, 58, 1013-1021.	1.1	7
90	Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108881.	1.6	7

#	ARTICLE	IF	CITATIONS
91	Sociodemographic Differences in Quality of Treatment to Medicaid Enrollees Receiving Buprenorphine. <i>Substance Abuse</i> , 2022, 43, 1057-1071.	1.1	7
92	Health Care Experiences of Latino Children in Emerging and Traditional Destinations. <i>Medical Care</i> , 2016, 54, 442-448.	1.1	6
93	Medicaid and CHIP Premiums and Access to Care: A Systematic Review. <i>Pediatrics</i> , 2016, 137, e20152440.	1.0	6
94	Medical Financial Burden Declined For Consumers In The Nongroup Market. <i>Health Affairs</i> , 2017, 36, 833-837.	2.5	6
95	Behavioral And Other Chronic Conditions Among Adult Medicaid Enrollees: Implications For Work Requirements. <i>Health Affairs</i> , 2019, 38, 660-667.	2.5	6
96	Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108424.	1.5	6
97	A national survey of state laws regarding medications for opioid use disorder in problem-solving courts. <i>Health and Justice</i> , 2022, 10, 14.	0.9	6
98	Trends In The Use Of Treatment For Substance Use Disorders, 2010â€”19. <i>Health Affairs</i> , 2022, 41, 696-702.	2.5	6
99	Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 492-503.	1.1	6
100	The response of substance use disorder treatment providers to changes in macroeconomic conditions. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 59-65.	1.5	5
101	Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder. <i>Medical Care</i> , 2021, 59, 393-401.	1.1	5
102	Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals. <i>Journal of Substance Abuse Treatment</i> , 2022, 136, 108658.	1.5	5
103	What Ecologic Analyses Cannot Tell Us About Medical Marijuana Legalization and Opioid Pain Medication Mortalityâ€”Reply. <i>JAMA Internal Medicine</i> , 2015, 175, 656.	2.6	4
104	Most Primary Care Physicians Provide Appointments, But Affordability Remains A Barrier For The Uninsured. <i>Health Affairs</i> , 2018, 37, 627-634.	2.5	4
105	Changes in primary care access at community health centers between 2012/2013 and 2016. <i>Health Services Research</i> , 2019, 54, 181-186.	1.0	4
106	Using Policy Tools to Improve Population Health â€” Combating the U.S. Opioid Crisis. <i>New England Journal of Medicine</i> , 2021, 385, 2113-2116.	13.9	4
107	A Bridge Too Far? Distance to Waivered Physicians and Utilization of Buprenorphine Treatment for Opioid use Disorder in West Virginia Medicaid. <i>Substance Abuse</i> , 2022, 43, 682-690.	1.1	4
108	Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey. <i>BMC Health Services Research</i> , 2022, 22, 418.	0.9	4

#	ARTICLE	IF	CITATIONS
109	Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder. <i>Medical Care</i> , 2019, 57, 667-672.	1.1	3
110	State Policymaking and Stated Reasons: Prenatal Care for Undocumented Immigrants in an Era of Abortion Restriction. <i>Milbank Quarterly</i> , 2021, 99, 693-720.	2.1	3
111	Comparing person-level matching algorithms to identify risk across disparate datasets among patients with a controlled substance prescription: retrospective analysis. <i>JAMIA Open</i> , 2022, 5, ooac020.	1.0	3
112	The Consequences of Removing Prior Authorization for Buprenorphine in Medicaid—Building an Evidence Base. <i>JAMA Health Forum</i> , 2022, 3, e220189.	1.0	3
113	Commentary on Kertesz & Gordon (2019): Don't abandon opioid prescription control efforts, reform them. <i>Addiction</i> , 2019, 114, 181-182.	1.7	2
114	Performance of a Predictive Model versus Prescription-Based Thresholds in Identifying Patients at Risk of Fatal Opioid Overdose. <i>Substance Use and Misuse</i> , 2021, 56, 396-403.	0.7	2
115	National Institute of Mental Health Recruitment Monitoring Policy and Clinical Trial Impact. <i>Contemporary Clinical Trials</i> , 2021, 103, 106312.	0.8	2
116	Buprenorphine Opioid Treatment During the COVID-19 Pandemic—Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1135.	2.6	2
117	Changes in Material Hardship During the First Year of the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2022, 3, e215213.	1.0	2
118	Medicaid Expansion, Chronic Disease, and the Next Chapter of Health Reform. <i>Journal of General Internal Medicine</i> , 2018, 33, 243-244.	1.3	1
119	Access to Care Among Individuals Who Experienced Medicaid Lockouts After Premium Nonpayment. <i>JAMA Network Open</i> , 2019, 2, e1914561.	2.8	1
120	Implementing parity for mental health and substance use treatment in Medicaid. <i>Health Services Research</i> , 2020, 55, 604-614.	1.0	1
121	Advanced Practice Providers and Buprenorphine Access in the United States After the Comprehensive Addiction and Recovery Act. <i>Psychiatric Services</i> , 2021, 72, 1358-1359.	1.1	1
122	Primary Care Appointment Availability and the ACA Insurance Expansions. <i>LDI Issue Brief</i> , 2017, 21, 1-4.	1.1	1
123	Effects of Medicaid Coverage on Receipt of Tobacco Dependence Treatment (TDT) among Medicaid Beneficiaries with Substance Use Disorder. <i>Health Services Research</i> , 2022, , .	1.0	1
124	Access to Primary Care in England—Reply. <i>JAMA Internal Medicine</i> , 2015, 175, 467.	2.6	0
125	Leveraging the Affordable Housing Sector to Respond to the Opioid Crisis. <i>Public Health Reports</i> , 2021, , 003335492110075.	1.3	0
126	Policy Strategies to Reduce Youth Recreational Marijuana Use. , 2017, , 66-69.		0

#	ARTICLE	IF	CITATIONS
127	Title is missing!. , 2020, 15, e0240080.		0
128	Title is missing!. , 2020, 15, e0240080.		0
129	Title is missing!.. , 2020, 15, e0240080.		0
130	Title is missing!.. , 2020, 15, e0240080.		0